A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
Recruiting
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Mayo Clinic, Phoenix, Arizona +7 locations
Conditions: Multiple Myeloma
Reach Out 2: Emergency Department-Initiated Hypertension Mobile Health Intervention Connecting Multiple Health Systems
Recruiting
Emergency department visits provide an opportunity to identify people with undiagnosed, untreated, or uncontrolled high blood pressure. In Reach Out, we will test whether a mobile health intervention yields a greater reduction in blood pressure than usual care among individuals identified with high blood pressure during a safety-net emergency department visit. Subsequently, we will estimate the reduction in heart attack, stroke, and dementia if Reach Out were implemented across all U.S. safety-n... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/21/2025
Locations: Hurley Medical Center, Flint, Michigan
Conditions: Hypertension
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
Recruiting
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado +4 locations
Conditions: Locally Advanced/Metastatic Solid Tumors
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Recruiting
To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Mutant IDH1 Inhibitor Olutasidenib
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Recruiting
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage inter-participant Dose Escalation Phase followed by a Dose Expansion Phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas +5 locations
Conditions: Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Mechanistic Studies of Psilocybin in Headache Disorders
Recruiting
In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect. This study will measure brain resting state functional connectivity (fMRI), central synaptic density (SV2A PET), peripheral markers of inflammation, circadian rhythm (actigraphy), and sleep (sleep EEG) in both migraine and healthy control participants before and one week after the... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
07/21/2025
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Migraine
LiveWell: Adapted DBT Skills Training for Metastatic Lung Cancer
Recruiting
Patients are living longer with metastatic lung cancer (i.e., metavivors) due to therapeutic advances, but face significant challenges. Most metavivors will ultimately die of cancer and must navigate the duality of living while dying. Unsurprisingly, metavivors endorse high psychological distress (e.g., anxiety, depression, illness non-acceptance), high symptom burden (e.g., fatigue, dyspnea, pain), and poor quality of life. Psychosocial interventions can improve outcomes, but existing paradigms... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Cancer Metastatic to Lung
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
Recruiting
The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma.. Study details include: 1. The study duration will be up to 72 weeks. 2. The treatment duration will be up to 68 weeks. 3. The visit frequency will be once every 4 weeks (Q4W).
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
07/21/2025
Locations: Research Site, Palmdale, California +83 locations
Conditions: Severe Asthma
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Recruiting
This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with acceptable side effects. This research study involves a combination of the below drugs: * Pembrolizumab (a type of monoclonal antibody) * Methotrexate (a type of anti-metabolite) * Temozolomide (a type of alkylating agent) * Rituximab (a type of antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Lymphoma, Primary Central Nervous System Lymphoma
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
Recruiting
The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Atrium Health Levine Cancer, Charlotte, North Carolina
Conditions: Cancer, Gastrointestinal Cancer
Study of ALTO-101 in Patients With Schizophrenia
Recruiting
This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
07/21/2025
Locations: Site 5038, Garden Grove, California +9 locations
Conditions: Schizophrenia, Cognitive Impairment
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
Recruiting
The primary purpose of the study is to assess the pharmacokinetics (PK) profile of pembrolizumab following subcutaneous (SC) injection of pembrolizumab coformulated with hyaluronidase, and to evaluate the objective response rate (ORR) of pembrolizumab (+) berahyaluronidase alfa SC in adult participants with Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL). There is no formal hypothesis to be tested for this st... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Clinical Research Alliance ( Site 0101), Westbury, New York +25 locations
Conditions: Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory